This past weekend, the CURE® staff was busy covering the American Society of Hematology (ASH) Annual Meeting.ASH is the largest blood cancer conference in ...

Biological differences may lead to aggressive tumor biology, according to data regarding racial disparities and the effect of obesity in patients with ...

The decline in how many people smoke (smoking prevalence) in England has nearly ground to a halt since the start of the pandemic, according to a new ...

While there have been many exciting advancements for the treatment of myeloproliferative neoplasms (MPNs) in 2023, Dr. Lucia Masarova, is hoping to see ...

When my Mom passed away when I was nine, her death fractured our family, making the time we spent together even more challenging. My siblings, significantly ...

The recent approval by the Food and Drug Administration (FDA) of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) or small ...

The FDA approved Iwilfin (eflornithine) to treat adult and pediatric patients with high-risk neuroblastoma.The Food and Drug Administration (FDA) approved ...

Durable responses were observed when Yescarta (axicabtagene ciloleucel) was used as a first-line therapy for patients with high-risk large B-cell lymphoma ...

The Food and Drug Administration (FDA) has ordered a supplemental Biologics License Application (sBLA) for the approval of Elahere (mirvetuximab ...

In over a decade working in the Civil Service, I learned that getting the Treasury to listen to why your policy area needed investment was not easy. In ...

The advent of antibody drug conjugates have been an exciting advancement for the treatment of metastatic breast cancer, as certain drugs can work in ...

Patients with relapsed or refractory KMT2A rearranged acute leukemia obtained durable minimal residual disease (MRD)-negative remission rates as a result of ...